Hims stock is climbing back from a steep drop within a base. Shares have climbed nearly 29% during the month and outperformed ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

Shares of telehealth company Hims & Hers Health are up Thursday afternoon. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.

Hims & Hers remains a compelling long-term play, with a resilient subscription-driven model, 85%+ retention, and 2.4 million ...

HIMS is transforming digital healthcare with AI-driven care, a booming subscriber base, and new tech leadership.

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the Stocks With Huge Catalysts on the Horizon. On July 9, Hims & Hers Health, ...

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

Unlike traditional care models that often leave patients to navigate treatment alone, Hims & Hers delivers access to a ...

Hims & Hers Health, Inc. HIMS has seen a surge in retail investor interest, which positions it as one of the most ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to controversial practices around the sale of compounded drugs. These drugs are ...

Hims & Hers is a telemedicine platform that offers patients access to a variety of medications, including for skin care, anxiety, sexual health, and even weight loss.

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.